Cigna Group vs Takeda Pharmaceutical
Cigna Group (CI), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Cigna Group is worth $78.5B on the stock market and Takeda Pharmaceutical $69.4B: Cigna Group is valued at 13% more. Cigna Group trades at 13.1 times earnings and Takeda Pharmaceutical at 310; operating margins in their latest fiscal years were 3.35% and 0.14%. Over the past year Cigna Group's share price has moved +10.1% and Takeda Pharmaceutical's +53.4%.
Key facts
- Cigna Group market value
- $78.5B
- Takeda Pharmaceutical market value
- $69.4B
- Cigna Group P/E
- 13.1
- Takeda Pharmaceutical P/E
- 310
- Cigna Group revenue
- $274.9BFY to 2025-12-31
- Takeda Pharmaceutical revenue
- $28.2BFY to 2026-03-31
- Superinvestors holding both
- 2
Market values as of .
| Measure | Cigna Group | Takeda Pharmaceutical |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $78.5Bhigher | $69.4Blower |
| Revenue | $274.9Bhigher | $28.2Blower |
| Earnings | $6Bhigher | -$954.4Mlower |
| Employees | 65,669higher | 47,029lower |
| Total assets | $157.9Bhigher | $97.1Blower |
| Valuation | ||
| P/E | 13.1lower | 310higher |
| P/S | 0.3lower | 2.5higher |
| P/B | 1.8 | — |
| Dividend yield | 2.06% | — |
| Profitability | ||
| Operating margin | 3.35%higher | 0.14%lower |
| Balance sheet | ||
| Net assets | $41.7Blower | $46.5Bhigher |
| Total liabilities | $116Bhigher | $50.6Blower |
| Total debt | $31.5Bhigher | $30.6Blower |
| Cash on hand | $7.7Bhigher | $3.7Blower |
| Price change | ||
| Today | -0.80%lower | +0.58%higher |
| 1 year | +10.1%lower | +53.4%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (2)
- Charles Brandes (founder)1.7% / 0.5%
- Richard Pzena0.4% / <0.1%
Cigna Group only (13)
Takeda Pharmaceutical only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio (under "Both": Cigna Group / Takeda Pharmaceutical). Who owns CI · Who owns TAK
More on Cigna Group
Further comparisons
Cigna Group against its closest peers
Takeda Pharmaceutical against its closest peers
Learn
Questions and answers
Which is bigger, Cigna Group or Takeda Pharmaceutical?
By market value, Cigna Group is the larger: $78.5B against $69.4B for Takeda Pharmaceutical. By revenue in its latest fiscal year, Cigna Group is the larger: $274.9B against $28.2B for Takeda Pharmaceutical.
Which has the higher P/E ratio?
Takeda Pharmaceutical: 310, against 13.1 for Cigna Group. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Cigna Group: 3.35%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Cigna Group: $31.5B, against $30.6B for Takeda Pharmaceutical. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Cigna Group and Takeda Pharmaceutical?
In their latest 13F filings, Charles Brandes (founder) and Richard Pzena hold both.
Cite this page
Funkfolio, “Cigna Group vs Takeda Pharmaceutical”, data as of 17 November 2026. https://funkfolio.com/compare/ci-vs-tak
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.